SCHEMBL4808003

SCHEMBL4808003

Cc1csc(Cl)c1-c1nc(OCc2ccc(F)cc2)ncc1-c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.39
CYP1A2 P05177 7/20 0.37
ALDH1A1 P00352 7/20 0.37
HSD17B10 Q99714 4/20 0.37
USP2 O75604 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
CASP1 P29466 3/20 0.37
CASP7 P55210 3/20 0.37
LMNA P02545 2/20 0.37
CYP3A4 P08684 4/20 0.36
CYP2C9 P11712 2/20 0.36
TSHR P16473 2/20 0.36
HPGD P15428 3/20 0.36
CYP2C19 P33261 3/20 0.36
KDM4E B2RXH2 1/20 0.36
PTGS2 P35354 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRA2 P47869 1/20 0.36
CSNK1A1 P48729 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4809154 0.90 CNR1 (0.45) CNR1CYP1A2ALDH1A1HSD17B10USP2
SCHEMBL4807874 0.83 CNR1 (0.47) CNR1CYP1A2ALDH1A1HSD17B10USP2
SCHEMBL4801977 0.77 CNR1 (0.63) CNR1
SCHEMBL14153824 0.73 CNR1 (0.54) CNR1
SCHEMBL4807989 0.73 CNR1 (0.54) CNR1
SCHEMBL4801542 0.72 CNR1 (0.55) CNR1CYP1A2ALDH1A1HSD17B10USP2
SCHEMBL4810311 0.72 CNR1 (0.60) CNR1CYP1A2ALDH1A1HSD17B10USP2
SCHEMBL4806021 0.70 CNR1 (0.54) CNR1
SCHEMBL4807959 0.68 CNR1 (0.64) CNR1
SCHEMBL4811918 0.67 CNR1 (0.46) CNR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405221-B2 Substituted pyrimidines MERCK & CO., INC. (US) 2008-07-29 US claimed
US-20050245554-A1 Substituted pyrimidines MERCK SHARP & DOHME CORP. 2005-11-03 US claimed
EP-1546115-A2 SUBSTITUTED PYRIMIDINES Merck & Co., Inc. (US) 2005-06-29 EP claimed
WO-2004029204-A2 SUBSTITUTED PYRIMIDINES MERCK & CO., INC. (US) 2004-04-08 WO claimed
US-7405221-B2 Substituted pyrimidines MERCK & CO., INC. (US) 2008-07-29 US disclosed
US-20050245554-A1 Substituted pyrimidines MERCK SHARP & DOHME CORP. 2005-11-03 US disclosed
EP-1546115-A2 SUBSTITUTED PYRIMIDINES Merck & Co., Inc. (US) 2005-06-29 EP disclosed
WO-2004029204-A2 SUBSTITUTED PYRIMIDINES MERCK & CO., INC. (US) 2004-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245554-A1 Substituted pyrimidines CNR1, CNR2, GPR119 CNR1 1/4885CYP1A2 1125/4885ALDH1A1 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.